Literature DB >> 7419607

Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells.

R M Wohlhueter, R S McIvor, P G Plagemann.   

Abstract

The mode of permeation of uracil, 5-fluorouracil, and orotic acid into cells has been investigated in four established cell lines (Novikoff rat hepatopma, P388 mouse leukemia, mouse L., and Chinese hamster ovary cells) in attempts to assess the rate-determining step(s) in their incorporation into the nucleotide pool and nucleic acids. Uracil and 5-fluorouracil shared a saturable transport system (Km = 5 to 15 mM) capable of rapid equilibration of these substrates across the cell membrane (t 1/2 at 25 degrees in first-order range of concentration = 25 to 58 sec). Thus it seems unlikely that transport is limiting the incorporation of uracil or fluorouracil. Their transport was inhibited by various nucleosides and hypoxanthine. Only the non-ionized form of fluorouracil was a substrate for the transporter; exclusion of charged pyrimidines may explain why orotate was not a substrate at physiological pH. Orotate permeated the cell membrane much more slowly (t 1/2 = 2890 to 6930 sec); its permeation was apparently non-mediated and rate-determining in the conversion of extracellular orotate to intracellular nucleotides.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7419607     DOI: 10.1002/jcp.1041040305

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  31 in total

1.  Dynamics of uracil and 5-fluorouracil in DNA.

Authors:  Jared B Parker; James T Stivers
Journal:  Biochemistry       Date:  2011-01-13       Impact factor: 3.162

Review 2.  Molecular mechanisms of drug resistance.

Authors:  J D Hayes; C R Wolf
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

3.  Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

Authors:  Chris G Twitty; Oscar R Diago; Daniel J Hogan; Cindy Burrascano; Carlos E Ibanez; Douglas J Jolly; Derek Ostertag
Journal:  Hum Gene Ther Methods       Date:  2015-12-01       Impact factor: 2.396

4.  The transport of pyrimidines into tissue rings cut from rat small intestine.

Authors:  J R Bronk; J G Hastewell
Journal:  J Physiol       Date:  1987-01       Impact factor: 5.182

5.  Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.

Authors:  Joana Savva-Bordalo; João Ramalho-Carvalho; Manuela Pinheiro; Vera L Costa; Angelo Rodrigues; Paula C Dias; Isabel Veiga; Manuela Machado; Manuel R Teixeira; Rui Henrique; Carmen Jerónimo
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

6.  Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors.

Authors:  Terence P F Gade; Ian M Buchanan; Matthew W Motley; Yousef Mazaheri; William M Spees; Jason A Koutcher
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

Review 7.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

8.  Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.

Authors:  G J Peters; J Lankelma; R M Kok; P Noordhuis; C J van Groeningen; C L van der Wilt; S Meyer; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Low electric field enhanced chemotherapy can cure mice with CT-26 colon carcinoma and induce anti-tumour immunity.

Authors:  A Plotnikov; D Fishman; T Tichler; R Korenstein; Y Keisari
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

Review 10.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.